Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy
| Autor: | I Stankuš, L Barsová, J Chalupa, V Hejzlarová, J Bartoš, M Holikova, I Richter, J Forster, M Sochor, J Dvořák |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Oncology medicine.medical_specialty medicine.medical_treatment Statistical difference Antineoplastic Agents Castration resistant chemistry.chemical_compound Prostate cancer Internal medicine Nitriles Phenylthiohydantoin medicine Humans Enzalutamide In patient Neoplasm Metastasis Aged Retrospective Studies Aged 80 and over Chemotherapy business.industry Retrospective cohort study Middle Aged medicine.disease Prostatic Neoplasms Castration-Resistant Abiraterone chemistry Benzamides Androstenes business |
| Zdroj: | Klinicka onkologie. 29:127-132 |
| ISSN: | 1802-5307 0862-495X |
| Popis: | Aim Enzalutamide and abiraterone represent new therapeutical options in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The aim of the presented study was retrospective analysis of clinical experience and efficacy of enzalutamide or abiraterone in the postchemo indication in patients with mCRPC. Patients and methods A total of 32 mCRPC patients were evaluated. All patients received one or more lines of chemotherapy. Twenty-three patients were treated by enzalutamide, nine patients were treated by abiraterone. We defined two parameters: over all survival and progression-free survival. Results The median follow-up was 6.5 months. A total of 10 patients treated by enzalutamide progressed (43.47%) and eight patients died (34.78%). A total of five patients treated by abiraterone progressed (55.56%) and one patient died (11.11%). We did not observe any statistical difference in over all survival (HR 0.2362, 95% CI 0.0295- 1.8942; p = 0.102) and in progression-free survival (HR 0.9853, 95% CI 0.2934- 3.308; p = 0.939) between enzalutamide and abirateron. Conclusion Our retrospective study demonstrated similar efficacy of enzalutamide and abiraterone in mCRPC patients previously treated by chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|